MIT Libraries logoDSpace@MIT

MIT
View Item 
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
  • DSpace@MIT Home
  • MIT Open Access Articles
  • MIT Open Access Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

On-demand manufacturing of clinical-quality biopharmaceuticals

Author(s)
Crowell, Laura E; Lu, Amos E; Love, Kerry R; Stockdale, Alan; Timmick, Steven M; Wu, Di; Wang, Yu Annie; Doherty, William; Bonnyman, Alexandra; Vecchiarello, Nicholas; Goodwine, Chaz; Bradbury, Lisa; Brady, Joseph R; Clark, John J; Colant, Noelle A; Cvetkovic, Aleksandar; Dalvie, Neil C; Liu, Diana; Liu, Yanjun; Mascarenhas, Craig A; Matthews, Catherine B; Mozdzierz, Nicholas J; Shah, Kartik A; Wu, Shiaw-Lin; Hancock, William S; Braatz, Richard D; Cramer, Steven M; Love, J Christopher; ... Show more Show less
Thumbnail
DownloadAccepted version (2.049Mb)
Terms of use
Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/
Metadata
Show full item record
Abstract
© 2018, Nature Publishing Group. All rights reserved. Conventional manufacturing of protein biopharmaceuticals in centralized, large-scale, single-product facilities is not well-suited to the agile production of drugs for small patient populations or individuals. Previous solutions for small-scale manufacturing are limited in both process reproducibility and product quality, owing to their complicated means of protein expression and purification1–4. We describe an automated, benchtop, multiproduct manufacturing system, called Integrated Scalable Cyto-Technology (InSCyT), for the end-to-end production of hundreds to thousands of doses of clinical-quality protein biologics in about 3 d. Unlike previous systems, InSCyT includes fully integrated modules for sustained production, efficient purification without the use of affinity tags, and formulation to a final dosage form of recombinant biopharmaceuticals. We demonstrate that InSCyT can accelerate process development from sequence to purified drug in 12 weeks. We used integrated design to produce human growth hormone, interferon a-2b and granulocyte colony-stimulating factor with highly similar processes on this system and show that their purity and potency are comparable to those of marketed reference products.
Date issued
2018
URI
https://hdl.handle.net/1721.1/134719
Department
Koch Institute for Integrative Cancer Research at MIT; Massachusetts Institute of Technology. Department of Chemical Engineering; Massachusetts Institute of Technology. Department of Mechanical Engineering
Journal
Nature Biotechnology
Publisher
Springer Science and Business Media LLC

Collections
  • MIT Open Access Articles

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

Login

Statistics

OA StatisticsStatistics by CountryStatistics by Department
MIT Libraries
PrivacyPermissionsAccessibilityContact us
MIT
Content created by the MIT Libraries, CC BY-NC unless otherwise noted. Notify us about copyright concerns.